|
Mr. Clarke joined the Mersana Board of Directors in the fall of 2007. Since 2006, Boyd has served as Chairperson of the Board of QLT Inc., a publicly traded biotech company focused on pharmaceutical products in the fields of ophthalmology and dermatology. From April 2002 to May 2006, he was CEO of Neose Technologies, Inc., a publicly listed biotech company focused on the development of protein therapeutics. From December 1999 through February 2002, Boyd served as CEO of Aviron, Inc., a biotech company developing vaccines, which was acquired by MedImmune, Inc., and was also Chairman from January 2001 through March 2002. From September 1996 through December 1999, Boyd was President and CEO of U.S. Bioscience, Inc., also a biotech company focused on products to treat cancer, which was also acquired by MedImmune. From 1977 to 1996 Boyd held a number of positions at Merck & Co., Inc., including being the first President of Pasteur-Merieux MSD, and most recently as Vice President of Merck Vaccines. Boyd was formerly on the BOD of Neose, as well as the Biotechnology Industry Association. He is also currently a director of Rib-X, a private organization focused on the design and development of novel small-molecule antibiotics. Boyd has a BS in Biochemistry and an MA in History from the University of Calgary. | 